tbuckley/cabot-search huggingface dataset:
Family history (FH) of women with breast cancer (BC) and acute myelogenous leukemia (AML).
Authors: K. A. Reiss, R. R. Yehia, D. Rangachari, A. Blackford, H. Carraway, V. Stearns, R. J. Arceci, J. E. Karp
Journal: Journal of Clinical Oncology (2010)

6580 Background: The increased incidence of AML in women with a personal history of BC has been attributed to prior treatment with chemotherapy and/or ionizing radiation. Alternatively, a positive association might be due to an inherited predisposition to both BC and AML. To test this hypothesis, we conducted a cross-sectional case-control study of women with AML ± BC. Methods: A total of 442 female patients with AML were treated at the Sidney Kimmel Cancer Center between 2003 and 2009. Cases included 59 women with a prior personal history of BC. These were compared to 120 randomly selected controls. Using retrospective chart review, we were able to assess FH for 55/59 cases and 99/120 controls. Overall, FH was available on 412 (93%) patients. Results: 78 of 412 (19%) AML patients had a positive FH of BC and/or ovarian cancer (OvC). FH rates for hematological malignancies or other types of solid tumors were not significantly different between the groups (Table). In contrast, 44% of cases had a positive FH for BC/OvC compared to 16% of controls. Moreover, 19 of 24 cases (80%) with a positive FH of BC/Ovc had ≥1 affected first-degree relative compared to 9 of 16 (56%) of controls. The median age at BC diagnosis was 55 (range: 30-74). The median interval between BC and AML was 4 years (range: 1-22); 7 (12%) cases were diagnosed with a second primary BC prior to their AML diagnosis (median interval 2 years, range: <1–14). Of the primary BC, 21 (75%) were invasive and 7 (25%) were intraductal; 28 BC (85%) were ER/PR positive and 2 (11%) were HER-2 positive; 54% of cases had received chemotherapy, 65.5% had received XRT for their BC. The 11q23 chromosomal rearrangement characteristic of treatment-related AML was most strongly associated with a previous history of BC (p = 0.023). Conclusions: Our results strongly suggest that the association between BC and AML is primarily due to an inherited cancer predisposition that confers an increased sensitivity to DNA damage and favors germ-line mutations in genes other than BRCA1 as the underlying mechanism. FH of malignancy Cases Controls X2(p value) Known 55 (93%) 99 (83%) 0.06 Any 38 (69%) 53 (53%) 0.06 BC/OvC 24 (44%) 16 (16%) 0.0002 Hematological 7 (13%) 17 (17%) 0.47 Other 24 (44%) 35 (35%) 0.31 No significant financial relationships to disclose.
Electronic self-report assessment for cancer: Results of a multisite randomized trial.
Authors: Donna Lynn Berry, Fangxin Hong, Barbara Halpenny, Qian Wang, Ann H. Partridge, Jesse R Fann, Seth Wolpin, William B Lober, Nigel Bush, Jaclyn Lee Fong Bosco, Upendra Parvathaneni, Dagmar Amtmann, Anthony Back
Journal: Journal of Clinical Oncology (2012)

9008 Background: Attending to symptoms and side effects promotes safe and effective delivery of cancer therapies. Providing focus to the patient’s report in the clinic can efficiently address the most important concerns, without extending visit times. The web-based electronic self report assessment for cancer (ESRA-C) and clinician summary has been shown to improve patient-clinician communication about symptoms and quality of life issues (SQI). The purpose of this trial was to evaluate the impact of an enhanced ESRA-C intervention (ESRA-C INT) on symptom outcomes. Methods: Patients (planned N=702) with all cancer types treated in stem cell transplant, medical oncology and radiation oncology at two comprehensive cancer centers used ESRA-C to self-report SQI during and after new anti-cancer therapy, with summary reports delivered to clinicians. Patients were randomized to standard ESRA-C (control) or ESRA-C INT adding the opportunity to self-monitor SQI between clinic visits and receive self-care SQI management education, plus custom coaching on how to report SQI to clinicians, all delivered via a secure web sites. We analyzed the intervention effect on Symptom Distress Scale (SDS) scores using a two-sided t-test and multivariate linear regression, adjusting for pre-selected covariates, including baseline SDS, age, service, and work status. Results: Among 757 patients (increased N due to involuntary attrition), demographic variables were balanced between groups except age (t=2.13; p=.03) with a younger INT group (mean 1.97 year difference). Of the 562 patients who completed final reports, the control group reported significantly higher SDS scores (t= 1.98; p = .048). A significant interaction between study group and age was observed; significantly lower SDS scores were found in the ESRA-C INT group among patients &gt; 50 years (-1.95; p=.002), and no significant difference among patients &lt; 50. Conclusions: Adding self-care and communication coaching to ESRA-C, a system to allow self-report and clinician notification of SQI, reduced symptom distress in a large sample of patients during and after active cancer treatment compared with ESRA-C alone. Patients over the age of 50, in particular, may benefit from the intervention.
Targeted tumor therapy with the TGF-beta2 antisense compound AP 12009 for the treatment of advanced solid tumors
Authors: H. Oettle, T. Seufferlein, R. Schmid, T. Luger, S. Ludwig, S. Schmaus, M. Beyer, D. Fischer, M. Hafner, K. Schlingensiepen
Journal: Journal of Clinical Oncology (2006)

14012 Background: TGF-β overexpression in advanced tumors is correlated with tumor-induced immunosuppression, proliferation and angiogenesis. Furthermore, it is a key factor for induction of epithelial to mesenchymal transition (EMT), thus promoting invasion and metastasis. Targeted tumor therapy by an antisense oligonucleotide has already been proven to be successful in tumor therapy: AP 12009, a TGF-β2-mRNA-specific antisense oligodeoxynucleotide, has shown strong clinical indication of efficacy including complete and lasting remissions in malignant glioma. Methods: Spurred by the highly encouraging clinical data in malignant glioma and strong anti-tumor activity in a wide variety of preclinical assays, clinical studies in further indications were initiated. A multi-center dose-escalation phase I/II trial with AP 12009 in patients suffering from advanced solid tumors was started in 2005. Primary endpoint is to assess the maximum tolerated dose (MTD) as well as the dose-limiting toxicity (DLT). AP 12009 is administered i.v. in 14-day cycles. Results: Preclinically, in human pancreatic cancer and melanoma cell cultures AP 12009 significantly reduced the TGF-β2 secretion of cancer cells, inhibited tumor cell proliferation, and blocked migration of cancer cells. Additionally, AP 12009 reversed TGF-β2 mediated immunosuppression induced by pancreatic carcinoma cells. In the ongoing clinical phase I/II dose-escalation study, two cohorts of tumor patients have already been treated intravenously with AP 12009 as of Dec 2005. Further dose escalations are ongoing. So far, no DLT, no possibly related SAEs and only seven possibly related AEs were observed. MTD is not yet reached. The majority of patients received more than the minimum number of two cycles, one of them received ten full cycles. First signs of efficacy could also be observed. Conclusions: In conclusion, the preclinical results with pancreatic cancer and malignant melanoma cell cultures as well as the successful clinical application of AP 12009 in the lead indication malignant glioma form a rational basis for the use of the antisense compound AP 12009 as targeted therapy of advanced, TGF-β2 overexpressing tumors. [Table: see text]
Chemotherapy-induced amenorrhea from adjuvant breast cancer treatment: The effect of taxanes
Authors: D. M. Mintzer, A. L. Davis, M. Klitus
Journal: Journal of Clinical Oncology (2004)

687 Background: Approximately 25% of breast cancer occurs in women younger than 50 years of age. Maintaining fertility may be an important issue for women undergoing adjvuant chemotherapy. Taxanes are being used increasingly in adjuvant chemotherapy treatment but their impact on menstrual function is not well established. We studied the effect of the addition of taxanes to standard adjuvant chemotherapy regimens on menstrual function. Methods: A retrospective chart review of breast cancer patients 50 years or younger from our center revealed 159 women who were premenopausal at the initiation of treatment. Data collected included the type of chemotherapy received, use of tamoxifen, and menopausal status before and after treatment. Women were designated “postmenopausal” if they had not resumed menses within one year of completing chemotherapy. Hormonal testing was not routinely performed. Results: 73 women received AC (doxorubicin, cyclophosphamide) or CAF (cyclophosphamide, doxorubicin, 5-FU) without a taxane, and 53 received AC or CAF followed by 12 weeks of a taxane–either paclitaxel (33 pts) or docetaxel (20 pts). The median age of the AC/CAF patients was 42 yo and the median age of the AC/CAF + taxane group was 45 yo. 54% of the AC/CAF patients received subsequent tamoxifen compared to 60% of the AC/CAF + taxane patients. After treatment, 48 % (51/106) of the non-taxane treated group retained menstrual function, whereas 57% (30/53) of the taxane-treated patients retained menstrual function. Conclusion: The addition of paciltaxel or docetaxel to AC/CAF adjuvant chemotherapy does not increase the likelihood of chemotherapy-induced amenorrhea. No significant financial relationships to disclose.
Prevalence of anal squamous intraepithelial lesions in HIV-positive and HIV-negative men who have sex with men in Thailand.
Authors: T. Chalermchai, A. H. Li, J. Ananworanich, N. Teeratakulpisarn, W. Sathainthammawit, C. Pakam, S. Chaithongwongwatthana, C. Shikuma, P. Phanuphak, N. Phanuphak
Journal: Journal of Clinical Oncology (2010)

1598 Background: Men who have sex with men (MSM) are at increased risk for high-grade squamous intraepithelial lesions (SIL), the putative precursor to anal cancer. Since 2006, the Thai Red Cross AIDS Research Centre (TRCARC) in Bangkok has offered anal cytology screening to MSM clients. Methods: Demographics, CD4+ T cell count, viral load, and anal cytologic (pap smear) and histologic (biopsy) specimens were collected as available from MSM who attended the TRCARC between February 1, 2008 and November 30, 2009. Chi-square analysis and Student's t-test were used to evaluate risk factors and SIL prevalence. Results: A total of 912 Thai MSM received anal cytology screening. Mean age was 31 years, and 65.8% (n = 600) were HIV-positive. Prevalence of abnormal anal cytology was 18.4%. HIV–positive MSM had higher prevalence of SIL than HIV-negative MSM (23.7% versus 8.3%, p < 0.001). Anal condyloma by clinical examination was detected in 11.2% of HIV-positive and 9.7% of HIV-negative patients (p = 0.496). Among HIV-positive MSM, 15.3% had atypical cells of undetermined significance (ASC- US), 8.2% had low-grade SIL (LSIL), and 0.2% had high-grade SIL (HSIL). Those with SIL were younger (29.9 vs. 32.2 years, p = 0.002) and had lower CD4+ T cell counts (283.9 vs. 372.2 cells/mm3, p < 0.001) than those with normal cytology. Among HIV-negative MSM, the prevalence of ASC-US, LSIL, and HSIL were 5.8%, 1.9%, and 0.6%. In follow-up, 91 MSM underwent a second pap smear, of these 11.0% progressed in cytologic grade, 28.6% regressed, and 60.4% were unchanged. The proportion of MSM with regression or progression of cytology did not differ by HIV infection (p = 0.905). Thirty-six men with SIL had high resolution anoscopy, and 35 underwent biopsy. Histology results were normal (14.3%), or were consistent with HPV infection (17.1%), AIN I (14.3%), AIN II (8.6%), AIN III (8.6%) and condyloma (31.4%). Conclusions: Prevalence of SIL is high among MSM in Thailand. Abnormal cytology was associated with lower CD4+ T-cell count and younger age among HIV-positive MSM. Histology confirmed high prevalence of AIN but did not correspond to pap cytology. Improved detection methods for pre-cancerous anal lesions are needed. No significant financial relationships to disclose.
Prognostic factors (PF) in advanced hepatocellular carcinoma (AHCC): Multivariate analysis and comparison between staging systems (SS) in patients (pts) treated at Memorial Sloan-Kettering Cancer Center (MSKCC)
Authors: F. D. Huitzil, M. Capanu, G. Jacobs, W. Smith, E. O’Reilly, M. Shah, G. K. Schwartz, L. B. Saltz, D. P. Kelsen, G. K. Abou-Alfa
Journal: Journal of Clinical Oncology (2007)

4601 Background: Several SS have been proposed in hepatocellular carcinoma. These include TNM, Okuda, Cancer of the Liver Italian Program (CLIP), Chinese University Prognostic Index (CUPI), and Barcelona Clinic Liver Cancer (BCLC). There is no consensus as to what constitutes the best SS for use by oncologists for pts with AHCC with no locoregional therapy options. We propose to define the PF and compare SS in this patient population. SS may help select pts for systemic therapy, predict outcome, and help in clinical trial design for AHCC. Methods: We retrospectively identified pts with AHCC treated at MSKCC between 2001 and 2006. Clinical, laboratory, tumor characteristics and all four SS were recorded. Survival (S) was measured from the date of development of AHCC to the date of death. S was estimated using Kaplan-Meier’s method, differences in S were tested using the log rank test. A Cox regression model was used for the multivariate analysis. A second Cox regression was done to compare SS and was expressed using the Akaike information (AI) criterion. AI helps determine which SS is the most informative of S. A low AI is favorable. Results: We identified 280 pts. Data on the first 101 pts analyzed are presented. Median age 61 years; 71% males, 29% females; 60% Caucasians, 9% Black, 24% Asians and 5% Hispanics. Etiologies included HCV 24%, HBV 38%, and alcohol 22%. Child Pugh score: A in 65% and B in 29% of pts. Multivariate analysis independent PF for S were albumin (p=0.0358), alkaline phosphatase (ALP) (p=0.001), identified etiology (p=0.008), abdominal pain (p=0.001) and liver tumor extent (more or less than 50% of the liver) (p=0.0043). AI ranked SS as follows: TNM 6 th (588.991), TNM 5 th (591.373), BCLC (541.095), Okuda (540.490), CLIP (537.8), and CUPI (526.483). CUPI S was 19.47 months (m) for low, 5.89 m for medium, and 1.36 m for high risk pts. Conclusions: Pts with AHCC who are treated by oncologists in this US-based population have distinct PF. CUPI provided the best prognostic information for our patient population. CUPI may be suggested as the SS to use clinically for AHCC. These results need prospective validation. No significant financial relationships to disclose.
Abstract 11182: Effect of Adaptive Servo Ventilation on Autonomic Nervous Balance: Analysis of Heart Rate Variavility by Wireless Holter ECG
Authors: Shoji Iwaya, Akiomi Yoshihisa, Takashi Owada, Makiko Miyata, Koichi Sugimoto, Takayoshi Yamaki, Hiroyuki Kunii, Kazuhiko Nakazato, Hitoshi Suzuki, Shu-ichi Saitoh, Yasuchika Takeishi
Journal: Circulation (2012)

Background: Activation of sympathetic nervous system plays a critical role in chronic heart failure (CHF) and is associated with adverse clinical outcome. Heart rate variability (HRV) is useful for...
Clinical features and outcome in primary breast sarcomas (BS): Analysis of a single-institution experience
Authors: T. Ramon y Cajal, J. Mazarico, A. Lopez Pousa, M. Quintana, N. Sala, M. Altabas, A. Sebio, L. Robert, C. Alonso, A. Barnadas
Journal: Journal of Clinical Oncology (2009)

e21520 Background: BS are characterised by local spread and recurrence. Controversy remains about local and adjuvant treatment. The objective of this retrospective study was to analyze clinical and pathological prognostic factors influencing the outcome of BS patients. Methods: We analyzed clinicopathological variables, treatment and outcome of 33 BS patients treated at our institution from 1966 to 2007. A single pathologist reviewed pathologic diagnoses. Kaplan Meier method was used to evaluate outcome. Mean age: 44 years (20–82y. Tumor size 57 (0–230) mm. Pathology: 17 cistosarcoma phylodes (CPh), 9 angiosarcoma, 2 extraesqueletical osteosarcoma, 2 fibrosarcomas, 1 liposarcoma, 1 leiomiosarcoma, 1 malignant fibrous histiocitoma (2.9%). Low-grade in 12, high-grade in 15 pts. Mastectomy in all but 8 patients. Adjuvant chemotherapy and radiotherapy in 9 and 7 patients. Pathological stage I- 12%, II- 65%, III- 9%, IV-3% Results: Median follow-up 71 (5–239) months. Median survival 160 months. Survival was 83%, 74% and 59% at 5, 10 and 15 year. 5/8 (62.5%) local excision patients needed rescue surgery due to local progression. 8/25 (32%) mastectomy patients progressed Local recurrence in 9 pts, distant 4 pts (radical rescue surgery in 10 pts). 7 pts death only 1 phyllodes. Mean 15-year survival for CPh was 169 vs 124 months for other histologies (p 0.06). In the univariate analysis we didn't found statistical differences according to clinical &amp; pathological factors, stage and recurrence, on OS or PFS. Conclusions: CPh have better prognosis than other BS although its stage or size tends to be higher. Radical surgery in BS should be always considered as first treatment option. High-grade non-phylodes BS types may be considered for adjuvant chemotherapy although there were non-statistical differences in OS. No significant financial relationships to disclose.
Combination carboplatin and pemetrexed for the treatment of platinum-sensitive recurrent ovarian cancer
Authors: N. S. Horowitz, R. T. Penson, S. M. Campos, J. Lee, D. L. Kendall, C. N. Krasner, S. T. Berlin, M. Roche, L. R. Duska, U. A. Matulonis
Journal: Journal of Clinical Oncology (2008)

5523 Background: More efficacious, less toxic combinations are needed to treat platinum-sensitive recurrent ovarian cancer. Pemetrexed (Pem) is a multitargeted antifolate that has a manageable toxicity profile and has been combined with carboplatin in other cancers. Methods: Phase II study of carboplatin AUC 5 with Pem 500 mg/m2 both administered IV on day 1, with Decadron, B12, and folate premedication, and given every 21 d for six cycles with the possibility of receiving 8 if benefit derived. Eligibility included platinum sensitive (>6 mos without progression after last platinum regimen), measurable (by RECIST) recurrent ovarian, peritoneal, or fallopian tube cancer, PS ≤ 2, ≤ 2 prior regimens for recurrence, and normal bone marrow, liver/renal function. Primary objective was response rate. Other endpoints included toxicities, time to progression (TTP), and survival. A RR of ≥ 31% was considered worthy of further phase III testing. Results: 45 patients have been enrolled, and accrual is complete. 1 pt was ineligible. 3 pts withdrew before 2 cycles were completed because of grade 3 fatigue/weakness, grade 3 diarrhea and a carboplatin reaction, respectively and were not evaluated for response. 27 pts completed at least 6 cycles. No dose reductions (DR’s) were required because of toxicities in 28 of 41 pts who received at least 2 cycles. 13 pts had DR’s as a result of myelosuppression or GI toxicity; 11 had one DR and 2 had two DR’s. 44 pts are evaluable for toxicities. Grade 3 and 4 toxicities are as follows: neutropenia (19 pts), platelets (11 pts), leukopenia (7 pts), anemia (4 pts), fatigue (4 pts), nausea (2 pts), diarrhea (2 pts), dizziness (2 pts), and 1 pt each experienced hypokalemia, vomiting, constipation, anorexia, memory impairment, pulmonary embolism. 14 pts had a carboplatin allergy. No significant rashes nor mucositis occurred. 41 pts were evaluable for RR, TTP, and survival. Overall RR was 61%; 1CR (2%), 24 PR’s (59%), 14 SD (34%), and 2 PD (5%). Median TTP was 4.6 months (95% CI 3.2 -5.9) while median PFS was 7.7 months (95% CI 6.7 - 10.1). Conclusions: Carboplatin/Pem is a well-tolerated regimen with significant activity in platinum-sensitive recurrent ovarian cancer. Further testing of this regimen in this population is warranted. Author Disclosure Employment or Leadership Consultant or Advisory Role Stock Ownership Honoraria Research Expert Testimony Other Remuneration Lilly Oncology
Stable Mixed Hematopoietic Chimerism in Dog Leukocyte Antigen–Identical Littermate Dogs Given Lymph Node Irradiation Before and Pharmacologic Immunosuppression After Marrow Transplantation
Authors: Rainer Storb, Cong Yu, Todd Barnett, John L. Wagner, H. Joachim Deeg, Richard A. Nash, Hans-Peter Kiem, Peter McSweeney, Kristy Seidel, George Georges, J. Maciej Zaucha
Journal: Blood (1999)
Phase II clinical study of combination therapy with irinotecan and S-1(IRIS) for inoperable recurrent advanced colorectal cancer (2nd report): For Hokkaido Gastrointestinal Cancer Study Group (HGCSG)
Authors: Y. Komatsu, S. Yuki, I. Iwanaga, M. Kudo, M. Tateyama, T. Amano, Y. Sakata, M. Asaka
Journal: Journal of Clinical Oncology (2007)

4105 Background: We planned to conduct a phase II clinical study of combination therapy with irinotecan and S-1, a new oral anticancer drug of the fluorinated pyrimidine type. We reported the interim reports of this study in colorectal cancer patients at ASCO 2006. Methods: The antitumor effect was the primary endpoint, while the safety, progression-free survival time, and median survival time were the secondary endpoints. The subjects were untreated patients with inoperable advanced colorectal cancer aged 20–75 years. Irinotecan was administered at a dose of 100 mg/m 2 (on days 1 and 15) as an intravenous infusion over 90 minutes, and oral S-1 (40 mg/m 2 ) was administered after breakfast and dinner and then withdrawn for 2 weeks. Results: Forty patients were enrolled in the present study. There were 23 men and 17 women. The median age was 62 years (range: 34 to 74 years). Two patients showed grade 4 neutropenia, but the next course could be given safely after dose reduction. Three patients had grade 3 diarrhea, but therapy could be continued with addition of an antidiarrhea drug. No other serious adverse reactions occurred (either hematological or non-hematological), and all patients could receive therapy safely on an outpatient basis. Forty pts. are evaluable for efficacy: RR was 52.5% (CR 1, PR 20, SD 17, PD 2, 95% CI, 37–68%) and Disease Control Rate (CR+PR+SD) was seen in 96.0% of pts. PFS of this regimen is 311 days. MST is not reached. Conclusions: IRIS therapy achieved a high response rate and could be given safely. These findings suggest that the therapy has potential as first-line treatment for inoperable advanced recurrent colorectal cancer. It seems that IRIS is a good treatment equal to FOLFIRI. Non-inferiority randomized phase III trial of IRIS vs. mFOLFOX6 (IFOX study) was planned, and it has been already started now. The latest data will be reported at the meeting. No significant financial relationships to disclose.